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regression coefﬁcients reﬂect better discrimination between presence or absence
of symptomatic OA. Analyses were performed crude and adjusted for age, sex
and BMI.
Results: In the sub-study (55% women, median age 56 years (IQR 50–61), BMI
30.0 kg/m2 (27.9–33.0)) 177 participants had symptomatic knee OA.
All MR abnormalities except for subchondral cysts were highly frequent both in
individuals with and without OA. The network graphs showed relations between
osteophytes within all compartments of the knee and between cartilage defects
on different locations. Within the same compartment, osteophytes and cartilage
defects were related.
Baker’s cysts showed the highest regression coefﬁcient (0.293) for presence of
symptomatic OA, followed by osteophytes and BMLs in the medial tibiofemoral
compartment (0.185–0.279), osteophytes in themedial trochlear facet (0.262), and
effusion (0.197). After adjustment for age, sex and BMI, the same abnormalities
identiﬁed OA best. The area under the curve of the logistic ridge regression
model including all assessed abnormalities was approximately 0.7. The ﬁgure
illustrates which abnormalities best identify symptomatic OA (A: Baker’s cyst,
effusion, osteophyte in medial trochlear facet, B: osteophytes in medial femoral
condyle and medial tibial plateau, C: BMLs in medial femoral condyle and medial
tibial plateau).
Figure 1
Conclusions: Baker’s cysts discriminate best between individuals with and
without symptomatic knee OA. Especially structural abnormalities as osteophytes
and BMLs in the medial side of the tibiofemoral joint and effusion add further
in discriminating symptomatic OA. Presence of Baker’s cysts may present as a
target for treatment.
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Background: Changes in the level of biomarkers speciﬁc of osteoarthritis (OA)
could help not only for the diagnosis but also for the monitoring of the disease
progression and efﬁcacy of a therapeutic intervention.
Objectives: The aim of this study was to investigate the effects of chondroitin
sulfate (CS) on the serum levels of biomarkers in patients with knee OA.
Methods:Seventy two patients with unilateral symptomatic kneeOAwere involved
in a post-authorization open-label study. Patients treated with CS (800 mg/day)
were evaluated 5 times from D-30 to 6-month. The primary outcome was the %
relative change in serum biomarkers (Coll2–1, Coll2–1NO2, Fib3–2). Secondary
outcomes were the evaluation of pain (VAS) and function (Lequesne’s Index).
Responders and non-responders were classiﬁed according to OMERACT-OARSI
recommendations. Finally, an original cut-off method was applied to categorize
patients and interpret variations in serum levels of Coll2–1.
Results: Patients from either ITT or PP populations showed no difference in the
serum biomarkers levels at baseline. Most of the biomarkers levels decreased
after 1 month of treatment but no signiﬁcant differences were reported. However
when considering responders and non-responders from the ITT population, a
signiﬁcant difference was found for Coll2–1 at 3 months (p=0.030) and 6 months
(p=0.038) (ACA approach). A decrease in pain (VAS) and an improvement in
function (LI) were recorded throughout the visits (p<0.01). The decrease in pain
was signiﬁcant at 1, 3 and 6 months in ITT and PP populations when compared to
baseline. The improvement of function was shown to be signiﬁcant after 6 months.
Finally, an intra-batch cut-off of 22% was determined for Coll2–1 assay based
on the variation of Coll2–1 between two blood collections in non-arthritic adult
subjects. This value allowed the deﬁnition of metabolic responders as patients
with variation of Coll2–1 by more than 22%.This means that a variation of 22% or
less in the serum level of Coll2–1 consisted in a variation related to homeostasis.
In contrast, a variation over this limit revealed either an increase or a decrease in
cartilage catabolism. Considering these categories, CS decreased Coll2–1 serum
levels between baseline and 1-month visit compared to the value of Coll2–1
before treatment (screening visit) which can be interpreted as a drastic reduction
of the proportion of patients with an increase of Coll2–1 over 22% (reduction from
13% to 3). It also consisted in a more important proportion of patients with a
decrease in Coll2–1.
Conclusions: CS was effective modulating the metabolic status of KOA patients
trough the reduction of Coll2–1 levels in responders and the disease’s symptoms.
Biomarkers are important tools for the monitoring of OA disease and of treatment.
The main goal in biomarker research is to qualify them as surrogate endpoints
in clinical trials. This study proposes a new approach for the analysis and the
interpretation of the variation in biomarker levels and introduces the notion of
metabolic responders.
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Background: Low Bone Mineral Density (BMD) was described in patients with
inﬂammatory arthritis. The data on its occurrence at preliminary phase of arthritis
onset is insufﬁcient. This study looks into the prevalence of low BMD in patients
with early inﬂammatory arthritis (EIA).
Methods: We reviewed the medical records and electronic ﬁles of all patients
with synovitis who attended rheumatology clinic between 1st December 2012
and 1st June 2015. Cases with features of synovitis less than two years were
only included in the study. The following data was captured; demographics,
time of symptom’s onset, results of Dual-energy X-ray absorptiometry (DEXA)
scan, and 25-hydroxyvitamin D level (ng/ml). Data are presented as the median
values and interquartile range (IQR). The prevalence was described as a fraction.
Mann-Whitney test was used to compare those with low BMD and those with
normal BMD.
Results: We identiﬁed 83 patients with inﬂammatory arthritis for less than two
years only 31 (37.3%) patients underwent DEXA scan. 26 (83.8%) were Emirati’s,
27 (87.0%) were females, and median age was 61 (IQR 57 -65 years). 9 (29%)
patients had normal BMD (T-score>-1.0 S.D), 13 (41.9%) patients had osteopenia
(T-score between -1.0 and -2.5 S.D), and 9 (29%) patients had osteoporosis
(T-score<- 2.5 S.D). Among osteoporotic patients, 4 (12.9%) had osteoporosis
at the lumbar spine only, 1 (3.2%) had osteoporosis at neck of the femur, and
4 (12.9%) patients had osteoporosis at both the lumbar spine and neck of the
femur. Age was a signiﬁcant predictor of low BMD in patients with EIA (Z-Score
is 2.357, p-value less than 0.02). However, ethnicity, gender, time lag before the
initiation of therapy, and vitamin D level did not predict the occurrence of low BMD.
Conclusions: Low BMD is a frequent manifestation in patients with EIA, especially
in the elder age group. Prospective studies are required to evaluate the long term
signiﬁcance of low BMD in EIA.
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Background: Polio is a devastating infectious disease that causes paralysis and
severe muscular atrophy. When any of the legs is affected, a low aBMD at the
corresponding hip is a common ﬁnding in DXA measurement.
Objectives: to study the inﬂuence of polio consequences on volumetric bone
density and cortical thickness using the 3D-DXA technology.
Methods: 22 patients of both sexes suffering post-polio syndromes (mean age
57±uffering pos were scanned using a GE iDXA system and both proximal
femurs were reconstructed using the 3D-DXA technology. 3D-DXA is based on
the registration of a 3D statistical model of the femoral shape and density onto
the 2D DXA image and provides measurements of volumetric BMD (vBMD) and
BMCof the trabecular and cortical bone as well as a quantiﬁcation of the cortical
thickness. The measurements at the leg affected by polio were compared by t-test
with those at the non-affected leg.
Results: Trabecular BMC was 22% lower (-1.8 g, p<0.01) and cortical BMC 19%
lower (-2.9 g, p<0.01) at the polio leg (total hip region). Similar ﬁndings were
observed for the vBMD: 18% decrease (-0.020 g/cm3, p<0.01) at the trabecular
region and a 2.3% decrease for the cortical bone (-0.024 g/cm3, p<0.01). The
proximal femur volume was also inferior (-12%, -9 cm3, p<0.01). The cortical
thickness was thinner at the polio leg (-12%, -0.2 mm, p<0.01).
Conclusions: A long period of decreased of mechanical charges, low muscle
strength, postural imbalance has dramatic consequences on bone development.
The analyses performed using the 3D-DXA technology indicates an overall
